BridgeBio Pharma, Inc. — Form 8-K
Filed July 22, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
BridgeBio announced FDA acceptance of its New Drug Application for encaleret to treat autosomal dominant hypocalcemia type 1 (ADH1), with a PDUFA target action date of May 8, 2027. The Phase 3 CALIBRATE trial met all pre-specified primary and key secondary efficacy endpoints, demonstrating normalization of calcium and PTH markers without need for supplements. The company is also enrolling a pediatric trial (CALIBRATE-PEDS) and plans to initiate RECLAIM-HP Phase 3 in chronic hypoparathyroidism, with an EU regulatory filing planned for H2 2026.
Why this rating
Major milestone for clinical-stage biotech: potential first-in-class therapy in orphan disease, ~$7.3B market cap. FDA acceptance reduces regulatory risk materially; May 2027 approval is achievable near-term catalyst. Blockbuster potential claimed, but market size unclear (~2,100 diagnosed U.S. cases as of April 2026). Meaningful but not transformational until commercial validation.
See more from July 22, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.